Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors
Clinical trial NCT05505877 · UNKNOWN
Trial details
- NCT number
- NCT05505877
- Sponsor
- Shanghai Gopherwood Biotech Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-10
- Primary completion
- 2024-10-31
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.